Johnson and Johnson Patent Lawsuit Settled

Angiotech Pharmaceuticals, Inc said it has reached a ‘favourable’ agreement with Johnson & Johnson’s subsidiary, Conor Medsystems to settle all outstanding patent litigation over Conor’s CoStar paclitaxel stent: terms of the settlement were not disclosed. ‘With this agreement now in place, Angiotech expects that the resources required to defend and enforce our intellectual property should decrease,’ said Dr. William Hunter, CEO of Angiotech.

At the time of the settlement, there was ongoing litigation in three jurisdictions: the UK, the Netherlands and Australia.

share this Article

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Recent Articles